Comparing two chemotherapy plans for older AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 75 years old.
- You have been diagnosed with acute myeloid leukemia (AML), but not certain rare subtypes like promyelocytic leukemia or leukemia with specific gene changes (PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, or BCR-ABL).
- You are generally active enough to take care of yourself (ECOG score 0-2).
- Your heart, liver, and kidney functions are within safe limits as judged by routine blood tests and an echocardiogram.
- You have not had prior chemotherapy for AML (except hydroxyurea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This study compares two chemotherapy combinations for older adults newly diagnosed with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or IDH1/IDH2). The goal is to see if the new combination works better and has fewer side effects than the standard one.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.